QQQ   423.32 (-0.59%)
AAPL   166.87 (-0.67%)
MSFT   406.17 (-1.38%)
META   503.81 (+1.95%)
GOOGL   156.66 (+0.77%)
AMZN   179.10 (-1.20%)
TSLA   149.73 (-3.68%)
NVDA   846.02 (+0.67%)
AMD   153.89 (-0.08%)
NIO   3.99 (+2.05%)
BABA   68.84 (+0.03%)
T   16.22 (+0.62%)
F   12.00 (-0.33%)
MU   113.05 (-2.82%)
GE   154.16 (-0.97%)
CGC   7.87 (+21.26%)
DIS   112.74 (-0.18%)
AMC   2.90 (-2.68%)
PFE   25.29 (-0.51%)
PYPL   62.12 (-1.80%)
XOM   118.13 (-0.42%)
QQQ   423.32 (-0.59%)
AAPL   166.87 (-0.67%)
MSFT   406.17 (-1.38%)
META   503.81 (+1.95%)
GOOGL   156.66 (+0.77%)
AMZN   179.10 (-1.20%)
TSLA   149.73 (-3.68%)
NVDA   846.02 (+0.67%)
AMD   153.89 (-0.08%)
NIO   3.99 (+2.05%)
BABA   68.84 (+0.03%)
T   16.22 (+0.62%)
F   12.00 (-0.33%)
MU   113.05 (-2.82%)
GE   154.16 (-0.97%)
CGC   7.87 (+21.26%)
DIS   112.74 (-0.18%)
AMC   2.90 (-2.68%)
PFE   25.29 (-0.51%)
PYPL   62.12 (-1.80%)
XOM   118.13 (-0.42%)
QQQ   423.32 (-0.59%)
AAPL   166.87 (-0.67%)
MSFT   406.17 (-1.38%)
META   503.81 (+1.95%)
GOOGL   156.66 (+0.77%)
AMZN   179.10 (-1.20%)
TSLA   149.73 (-3.68%)
NVDA   846.02 (+0.67%)
AMD   153.89 (-0.08%)
NIO   3.99 (+2.05%)
BABA   68.84 (+0.03%)
T   16.22 (+0.62%)
F   12.00 (-0.33%)
MU   113.05 (-2.82%)
GE   154.16 (-0.97%)
CGC   7.87 (+21.26%)
DIS   112.74 (-0.18%)
AMC   2.90 (-2.68%)
PFE   25.29 (-0.51%)
PYPL   62.12 (-1.80%)
XOM   118.13 (-0.42%)
QQQ   423.32 (-0.59%)
AAPL   166.87 (-0.67%)
MSFT   406.17 (-1.38%)
META   503.81 (+1.95%)
GOOGL   156.66 (+0.77%)
AMZN   179.10 (-1.20%)
TSLA   149.73 (-3.68%)
NVDA   846.02 (+0.67%)
AMD   153.89 (-0.08%)
NIO   3.99 (+2.05%)
BABA   68.84 (+0.03%)
T   16.22 (+0.62%)
F   12.00 (-0.33%)
MU   113.05 (-2.82%)
GE   154.16 (-0.97%)
CGC   7.87 (+21.26%)
DIS   112.74 (-0.18%)
AMC   2.90 (-2.68%)
PFE   25.29 (-0.51%)
PYPL   62.12 (-1.80%)
XOM   118.13 (-0.42%)
Free Trial
OTCMKTS:WXXWY

WuXi Biologics (Cayman) (WXXWY) Stock Price, News & Analysis

→ Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad)
Free WXXWY Stock Alerts
$3.33
+0.06 (+1.83%)
(As of 04/17/2024 ET)
Compare
Today's Range
$3.31
▼
$3.38
50-Day Range
$3.27
▼
$5.27
52-Week Range
$3.24
▼
$13.84
Volume
185,935 shs
Average Volume
275,035 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartHeadlinesShort Interest
WXXWY stock logo

About WuXi Biologics (Cayman) Stock (OTCMKTS:WXXWY)

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People's Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.

WXXWY Stock Price History

WXXWY Stock News Headlines

April 16, 2024 | finance.yahoo.com
WuXi Biologics (Cayman) Inc (1FW1.SG)
April 11, 2024 | americanbankingnews.com
WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Short Interest Update
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
April 2, 2024 | markets.businessinsider.com
Wuxi Biologics: A Strong Buy Based on Robust Sales Growth, Strategic Expansion, and Financial Stability
March 26, 2024 | prnewswire.com
WuXi Biologics Reports Solid 2023 Annual Results
March 22, 2024 | prnewswire.com
WuXi Biologics Named to CDP 'A List' for Water Security
March 8, 2024 | msn.com
Hong Kong Stocks: WuXi Biologics Shares Tumble on US Biotech Bill Concerns
March 5, 2024 | finance.yahoo.com
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
February 21, 2024 | prnewswire.com
WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics
February 14, 2024 | markets.businessinsider.com
Wuxi Biologics: Navigating the Biosecure Act with Resilience and Optimism
January 31, 2024 | finance.yahoo.com
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland
January 30, 2024 | markets.businessinsider.com
Wuxi Biologics (Cayman) Buy Rating: Growth Potential and Strong Compliance Standards
January 28, 2024 | bloomberg.com
WuXi Bio Denies Military Ties After Shares Slumped on US Bill
January 26, 2024 | finance.yahoo.com
WuXi AppTec, Wuxi Bio Tumble as US Lawmakers Propose Ban
January 26, 2024 | finance.yahoo.com
US lawmaker moves bill to ban Chinese biotech firms from federal contracts, alleging complicity with military
January 26, 2024 | finance.yahoo.com
Chinese Biotech Stocks Plunge on Proposed U.S. Legislation
January 24, 2024 | finance.yahoo.com
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect
January 23, 2024 | finance.yahoo.com
WuXi Biologics (Cayman) Inc. (WXXWY)
January 23, 2024 | morningstar.com
WuXi Biologics (Cayman) Inc ADR WXXWY
January 17, 2024 | finance.yahoo.com
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™
January 12, 2024 | markets.businessinsider.com
Wuxi Biologics: A Buy Rating on Robust Growth and Strong Pipeline Prospects
January 10, 2024 | finance.yahoo.com
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates
January 8, 2024 | finance.yahoo.com
WuXi Biologics to Increase Manufacturing Capacity in Massachusetts
December 26, 2023 | morningstar.com
WuXi Biologics (Cayman) Inc ADR
December 12, 2023 | finance.yahoo.com
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index
December 8, 2023 | finance.yahoo.com
WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating
See More Headlines
Receive WXXWY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for WuXi Biologics (Cayman) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:WXXWY
CUSIP
N/A
CIK
N/A
Web
www.wuxibiologics.com.cn
Phone
8651081831205
Fax
N/A
Employees
12,740
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2024 Cover
The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Ge Li Ph.D. (Age 57)
    Founder & Chairman
  • Dr. Zhisheng Chen (Age 51)
    CEO & Executive Director
    Comp: $621.73k
  • Dr. Weichang Zhou Ph.D. (Age 60)
    Honorary President of Global Biologics Development, Senior Advisor to CEO & Non-Executive Director
    Comp: $417.66k
  • Mr. Ming Tu (Age 56)
    CFO & Executive VP
  • Ms. Tang Shaogui M.B.A.
    VP and Head of Global Communications, Operations & ESG
  • Dr. Sherry Gu (Age 53)
    Chief Technology Officer and Executive VP of Global Biologics Development Department
  • Dr. Jijie Gu (Age 58)
    Executive VP & Chief Scientific Officer
  • Ms. Eileen Wang
    IR Senior Director
  • Ms. Cong Ding J.D.
    VP & Head of Legal Department
  • He Wang
    Chief Compliance Officer, Senior VP and Head of Global Compliance & Risk Management

Key Competitors

View All Competitors

WXXWY Stock Analysis - Frequently Asked Questions

How have WXXWY shares performed in 2024?

WuXi Biologics (Cayman)'s stock was trading at $7.45 on January 1st, 2024. Since then, WXXWY shares have decreased by 55.3% and is now trading at $3.33.
View the best growth stocks for 2024 here.

Are investors shorting WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 60,300 shares, an increase of 119.3% from the March 15th total of 27,500 shares. Based on an average daily volume of 305,200 shares, the short-interest ratio is currently 0.2 days.
View WuXi Biologics (Cayman)'s Short Interest.

How do I buy shares of WuXi Biologics (Cayman)?

Shares of WXXWY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:WXXWY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
GoldenCrest Metals
Next President (Not Trump. Not Biden.)
The Freeport Society
Biden’s $374B Giveaway Into This Sector
DTI
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research